Bay­er AG taps Pep­tiDream in bil­lion-dol­lar deal

Con­tin­u­ing to beef up its pipeline in the wake of this year’s string of R&D deals, Bay­er AG has be­come the lat­est Big Phar­ma part­ner to team up with Japan’s Pep­tiDream.

Bay­er is pay­ing Pep­tiDream an undis­closed up­front pay­ment, and could fork over as much as $1.11 bil­lion in mile­stone pay­ments for help dis­cov­er­ing and de­vel­op­ing pep­tide ther­a­peu­tics.

As part of the deal, Pep­tiDream will use its plat­form tech to iden­ti­fy macro­cyclic/con­strained pep­tides against mul­ti­ple tar­gets of in­ter­est se­lect­ed by Bay­er, and op­ti­mize hit pep­tides in­to ther­a­peu­tic pep­tides or small mol­e­cules. Bay­er will have the right to de­vel­op and com­mer­cial­ize all com­pounds re­sult­ing from the col­lab­o­ra­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.